Biotest Pharmaceuticals Announces Strategic Long-Term
Manufacturing, Supply and License Agreement
BOCA RATON, Fla., Jan. 10, 2013 /PRNewswire/ -- Biotest
Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of
Biotest AG (Dreieich, Germany),
today announced it has entered into a strategic long-term
manufacturing, supply, and license agreement with ADMA Biologics,
Inc. (ADMA).
Under the terms of the agreement, ADMA has agreed to purchase
exclusively from BPC its worldwide requirements of RSV (Respiratory
Syncytial Virus) Immune Globulin manufactured from human plasma
containing RSV antibodies. The initial term of the agreement
is for ten years. BPC will receive payment for manufacturing
services provided under the agreement as well as a percentage
royalty on ADMA's product revenues up to a specified maximum. In
exchange, BPC has agreed to provide manufacturing services and
granted ADMA a license to use BPC's proprietary fractionation and
purification manufacturing process for Intravenous Immune
Globulin.
"We are very pleased to partner with ADMA on their lead product
candidate. Our ability to provide specialized contract
manufacturing services will enable us to diversify our future
revenue sources," stated Jordan
Siegel, Chief Executive Officer of BPC.
About Biotest Pharmaceuticals Corporation
Biotest
Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest
AG, researches, develops and manufactures biotherapeutic products
with a specialization in immunology and hematology. BPC is a leader
in the collection of source plasma and is currently involved in the
development of plasma protein products and various hyperimmune (IG)
products. The Company owns and manages twelve plasmapherisis
centers across the United States
and a state-of-the-art manufacturing facility in Boca Raton, Florida. The Company employs
more than 700 people in the U.S.
About Biotest AG
Biotest AG is a provider of
pharmaceutical and biotherapeutic drugs. With a value added chain
that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialized primarily in the areas of
application of clinical immunology, hematology and intensive
medicine. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
hematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of
plasma cells. Biotest has more than 1.600 employees worldwide. The
preference shares of Biotest AG are listed in the SDAX on the
Frankfurt stock exchange.
Disclaimer
This document contains forward-looking statements on overall
economic development as well as on the business, earnings,
financial and assets position of Biotest AG and its subsidiaries.
These statements are based on current plans, estimates, forecasts
and expectations of the company and are thus subject to risks and
elements of uncertainty that could result in significant deviation
of actual developments from expected developments. The
forward-looking statements are only valid at the time of
publication. Biotest does not intend to update the forward-looking
statements and assumes no obligation to do so.
Contact
Main Number: 561-989-5800
www.biotestpharma.com
media@biotestpharmaceuticals.com
SOURCE Biotest Pharmaceuticals Corporation